← boardnext 2026-10-31next 2027-11-01next 2028-04-15
RYTM
Rhythm Pharmaceuticals, Inc.distress 0/10 · well-funded / low risk$101.54-2%today-14% from 52w high
Metabolic / Obesity 4
Lead: acquired hypothalamic obesity · target MC4R · est. market ~$15B (approx, global)
Revenue
$60M
Liquidity
$341M
Runway
2.9 yrs
Shares 1y
+3%
Price & events
-6.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.3%
1D
-4.3%
1W
-4.4%
1M
+19.2%
3M
-1.3%
6M
+15.6%
1Y
+103.9%
2Y
+407.2%
5Y
+234.5%
All
Overview
- Market Cap
- $6.96B
- Enterprise Value
- $7.00B
- Volume
- 27.67K
- 52 Week Range
- $75.82 – $118
- Total Shares
- 68.53M
- Float Shares
- 55.67M
- Short %
- 14.20%
- % Held by Insiders
- 0.77%
- % Held by Institutions
- 110.22%
- RVOL
- 0.03x
- Beta
- 1.88
Pipeline stages · 4 programs
Setmelanotide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Part C: RM-718, Part D: RM-718
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Bivamelagon
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
LB54640MC4R
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 9 trials · 5 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10-31 Estimated 50% readout ~2026-12-15 | Phase 2 | Setmelanotide | Prader-Willi Syndrome, Obesity, Hyperphagia | — | active not recruiting |
| 2027-03-13 Estimated 50% readout ~2027-05-27 | Phase 3 | Setmelanotide | Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia, Childhood-onset Combined Pituitary Hormone Deficiency, Pituitary Stalk Interruption Syndrome | — | recruiting |
| 2027-10-30 Estimated 50% readout ~2028-01-13 | Phase 3 | Setmelanotide | Obesity Associated With Defects in Leptin-melanocortin Pathway | — | enrolling by invitation |
| 2027-11-01 Estimated 50% readout ~2027-12-16 | Phase 1/2 | Part C: RM-718, Part D: RM-718 | Hypothalamic Obesity, Prader-Willi Syndrome, PWS | — | recruiting |
| 2028-04-15 Estimated 50% readout ~2028-05-30 | Phase 2 | Bivamelagon | Hypothalamic Obesity | — | enrolling by invitation |
Show all 9 trials · 4 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-02-09 | Phase 2 | LB54640 | Hypothalamic Obesity | — | completed |
| 2025-12-22 | Phase 3 | Setmelanotide | Obesity, Genetic Obesity | — | active not recruiting |
| 2025-03-18 | Phase 3 | Setmelanotide | Hypothalamic Obesity | — | active not recruiting |
| 2025-01-09 | Phase 2/3 | Setmelanotide | Obesity Associated With Defects in Leptin-melanocortin Pathway | — | completed |
Catalyst news & presentations · 18
- in 2026Guided 40%trial initiationsecondaryPhase 3bivamelagon · Initiate pivotal Phase 3 trialSEC 8-K
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026readoutPhase 3setmelanotide · Topline data from Phase 3 EMANATE trial across four substudies.SEC 8-K
- first half of 2026enrollment completesecondaryPhase 3setmelanotide · Complete enrollment in Phase 3 substudySEC 8-K
- ENDO 2026conferencedata presentationsecondaryMC4R agonists · Multiple new data presentations at ENDO 2026PR wire
- second quarter of 2026chmp opinionCHMP (EU)setmelanotide · CHMP opinion anticipatedSEC 8-K
- second quarter of 2026regulatory submissionFiled (NDA/BLA)setmelanotide · EC decision on expanded marketing authorizationSEC 8-K
- first quarter of 2026readoutPhase 3setmelanotide · Topline data from 12-patient Japanese cohortSEC 8-K
- first quarter of 2026enrollment completesecondaryPhase 1RM-718 · Complete enrollment in Phase 1 Part C trialSEC 8-K
- March 20, 2026PDUFAPDUFAsetmelanotide · Updated PDUFA goal date for sNDASEC 8-K
- 2025-11-06pdufa extensionsetmelanotide · FDA extended review period by three months; additional sensitivity analyses requestedSEC 8-K
- third quarter of 2025regulatory submissionFiled (NDA/BLA)setmelanotide · Planned sNDA submission to FDA and Type II variation to EMA for setmelanotide in acquired hypothalamic obesity.SEC 8-K
- 2025-07-09readoutPhase 2bivamelagon · Topline results from Phase 2 trial showed BMI reductions at 14 weeks.SEC 8-K
- second quarter of 2025readoutsetmelanotide · Topline data readout from global trial of setmelanotide in patients with acquired hypothalamic obesity.SEC 8-K
- first quarter of 2025trial initiationsecondaryPhase 3setmelanotide · Enroll first patients in congenital HO substudy of Phase 3 trial.SEC 8-K
- first quarter of 2025trial initiationsecondaryPhase 1RM-718 · Begin dosing in Part C of Phase 1 trial of RM-718.SEC 8-K
- first quarter of 2025enrollment completesecondaryPhase 2bivamelagon · Complete enrollment in Phase 2 trial of bivamelagon in acquired HO.SEC 8-K
- 2025-03-14withdrawalsetmelanotide · Termination of licensing agreement with RareStone for setmelanotide in China, including repayment of $6.3 million.SEC 8-K
Approved drugs (1)
- IMCIVREESETMELANOTIDE ACETATE2020 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $140 (+38% upside) · 15 analysts
- 2026-07-07RBC CapitalOutperform
- 2026-06-16Canaccord GenuityBuy
- 2026-06-15Wells FargoOverweight
- 2026-05-07Canaccord GenuityBuy
- 2026-05-06Wells FargoOverweight
- 2026-05-06RBC CapitalOutperform
Competitors — MC4R
- none identified
Recent news
- 2026-07-21Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm - Morningstar
- 2026-07-21Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm - PR Newswire
- 2026-07-21RYTM stock trades around recent range as Rhythm Pharmaceuticals highlights setmelanotide growth - Ad-hoc-news.de
- 2026-07-21Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Yahoo Finance
- 2026-07-21Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - GlobeNewswire
- 2026-07-21Rhythm Pharmaceuticals schedules live Q2 results webcast Aug. 4 - Stock Titan
- 2026-07-21Price-Driven Insight from (RYTM) for Rule-Based Strategy - Stock Traders Daily
- 2026-07-20Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Strong Buy Ratings Signal Potential 31% Upside - DirectorsTalk Interviews
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.